Table 1.
Characteristics of the patients in the sufentanil and control groups*
| Sufentanil Group (n=40) |
Control Group (n=40) |
P value | |
|---|---|---|---|
| Age (y) | 60.02±8.46 | 60.48±7.50 | 0.791 |
| Male gender | 27 (67.5) | 25 (62.5) | 0.639 |
| Height (cm) | 164.25±10.02 | 165.38±9.45 | 0.607 |
| Weight (kg) | 71.08±14.29 | 68.65±12.00 | 0.414 |
| Body surface area (m²) | 1.74±0.20 | 1.75±0.19 | 0.826 |
| Preoperative ejection fraction (%) | 44.25±5.94 | 43.75±6.18 | 0.713 |
| Hypertension | 21 (52.5) | 24 (60.0) | 0.499 |
| HLP | 32 (80.0) | 29 (72.5) | 0.431 |
| Cross-clamp time (min) | 50.48±4.71 | 50.63±8.38 | 0.922 |
| Cardiopulmonary bypass time (min) | 78.72±6.70 | 82.01±13.15 | 0.165 |
| Intubation time (h) | 10.39±1.17 | 12.19±2.81 | <0.001 |
| ICU stay (d) | 44.72±1.69 | 44.94±8.18 | 0.867 |
HLP, Hyperlipidemia; ICU, Intensive care unit
*
Data are presented as mean±SD, n (%)